The risk factors and prevention of stroke in atrial fibrillation
Stroke is one of the top three causes of death in the population and a leading cause of disability in the elderly; ischemic stroke (IS) constitutes a major portion (70–85%) of all strokes so its prevention s a relevant problem of modern medicine. Among the risk factors RFs) of stroke, nonvalvular...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2014-10-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/438 |
| _version_ | 1797876538471874560 |
|---|---|
| author | V. A. Parfenov S. V. Verbitskaya |
| author_facet | V. A. Parfenov S. V. Verbitskaya |
| author_sort | V. A. Parfenov |
| collection | DOAJ |
| description | Stroke is one of the top three causes of death in the population and a leading cause of disability in the elderly; ischemic stroke (IS) constitutes a major portion (70–85%) of all strokes so its prevention s a relevant problem of modern medicine. Among the risk factors RFs) of stroke, nonvalvular atrial fibrillation (AF) is of great ignificance, which occurs in persons over 70 years of age in pproximately 5–10% of cases and increases the risk of IS 3–4-fold.The review analyzes RFs for stroke in AF. The CHA2DS2-VASc scale encompassing several RFs is noted to be informative and easy-to-use. There are data of large-scale randomized trials that show that novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) are as good as warfarin or offer an advantage over the latter, by more substantially decreasing the risk of stroke and reducing the likelihood of profuse bleeding, intracranial hemorrhage in particular. There is evidence for the efficacy of rivaroxaban in the secondary prevention of stroke. The authors provide their experience with patient management to prevent recurrent cardioembolic stroke.In our country, most patients who have sustained IS or transient ischemic attack in the presence of AF do not take warfarin due to the fact that it is difficult to regularly monitor the international normalized ratio (INR). It is noted that the administration of the novel anticoagulants, which differs from that of warfarin, does not require INR monitoring and can increase the number of patients on anticoagulant therapy and therefore reduce the incidence of stroke in the presence of AF. |
| first_indexed | 2024-04-10T02:03:41Z |
| format | Article |
| id | doaj.art-fb16efb2810e4695bd5250e4a5584040 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:03:41Z |
| publishDate | 2014-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-fb16efb2810e4695bd5250e4a55840402023-03-13T08:42:14ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422014-10-0163556010.14412/2074-2711-2014-3-55-60425The risk factors and prevention of stroke in atrial fibrillationV. A. Parfenov0S. V. Verbitskaya1I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaStroke is one of the top three causes of death in the population and a leading cause of disability in the elderly; ischemic stroke (IS) constitutes a major portion (70–85%) of all strokes so its prevention s a relevant problem of modern medicine. Among the risk factors RFs) of stroke, nonvalvular atrial fibrillation (AF) is of great ignificance, which occurs in persons over 70 years of age in pproximately 5–10% of cases and increases the risk of IS 3–4-fold.The review analyzes RFs for stroke in AF. The CHA2DS2-VASc scale encompassing several RFs is noted to be informative and easy-to-use. There are data of large-scale randomized trials that show that novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) are as good as warfarin or offer an advantage over the latter, by more substantially decreasing the risk of stroke and reducing the likelihood of profuse bleeding, intracranial hemorrhage in particular. There is evidence for the efficacy of rivaroxaban in the secondary prevention of stroke. The authors provide their experience with patient management to prevent recurrent cardioembolic stroke.In our country, most patients who have sustained IS or transient ischemic attack in the presence of AF do not take warfarin due to the fact that it is difficult to regularly monitor the international normalized ratio (INR). It is noted that the administration of the novel anticoagulants, which differs from that of warfarin, does not require INR monitoring and can increase the number of patients on anticoagulant therapy and therefore reduce the incidence of stroke in the presence of AF.https://nnp.ima-press.net/nnp/article/view/438risk factors for ischemic strokecha2ds2-vasc scale for stroke riskprevention of strokewarfarinrivaroxabandabigatranapixaban |
| spellingShingle | V. A. Parfenov S. V. Verbitskaya The risk factors and prevention of stroke in atrial fibrillation Неврология, нейропсихиатрия, психосоматика risk factors for ischemic stroke cha2ds2-vasc scale for stroke risk prevention of stroke warfarin rivaroxaban dabigatran apixaban |
| title | The risk factors and prevention of stroke in atrial fibrillation |
| title_full | The risk factors and prevention of stroke in atrial fibrillation |
| title_fullStr | The risk factors and prevention of stroke in atrial fibrillation |
| title_full_unstemmed | The risk factors and prevention of stroke in atrial fibrillation |
| title_short | The risk factors and prevention of stroke in atrial fibrillation |
| title_sort | risk factors and prevention of stroke in atrial fibrillation |
| topic | risk factors for ischemic stroke cha2ds2-vasc scale for stroke risk prevention of stroke warfarin rivaroxaban dabigatran apixaban |
| url | https://nnp.ima-press.net/nnp/article/view/438 |
| work_keys_str_mv | AT vaparfenov theriskfactorsandpreventionofstrokeinatrialfibrillation AT svverbitskaya theriskfactorsandpreventionofstrokeinatrialfibrillation AT vaparfenov riskfactorsandpreventionofstrokeinatrialfibrillation AT svverbitskaya riskfactorsandpreventionofstrokeinatrialfibrillation |